Phase 1 · NCT05445232
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
A Multiple-Dose Drug-Drug Interaction Study to Determine the Effect of LY3437943 on Drug Metabolizing Enzymes
CompletedVerified
Trial registry record
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
- ClinicalTrials.gov ID
- NCT05445232
- Indication
- Obesity
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 32
- Status
- Completed
- Interventions
- Drug: LY3437943; Drug: Midazolam; Drug: Warfarin; Drug: Caffeine
- Comparator
- Not reported
- Eligible ages
- 18 Years – 70 Years
- Locations
- 2 sites · United States
- Study start
- 8 Jul 2022
- Primary completion
- 24 Feb 2023
- Study completion
- 24 Feb 2023
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 18 Apr 2023
Endpoints
Primary
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam; PK: Maximum Observed Concentration (Cmax) of Midazolam; PK: AUC[0-∞] of Warfarin; PK: Cmax of Warfarin; PK: AUC[0-∞] of Caffeine; PK: Cmax of Caffeine